Coming soon: Rebody is not currently taking orders for the peptide products discussed here. This guide covers the research and the product facts worth checking before any future offer opens.
The short answer
TB-500 is the actin-fragment recovery specialist. A complete label turns that biology into a clear routine by naming the exact seven-amino-acid substance, concentration, injection volume, dose, and supply.
Options at a glance
| Option | What changes | What must be verified | Boundary |
|---|---|---|---|
| 5 mg TB-500 vial | Total active and refill burden | Exact identity, concentration, supply | Not a dose by itself |
| 10 mg TB-500 vial | Total active and up-front price | Beyond-use date and cost per day | Not evidence of a stronger result |
| Weekly routine | Handling frequency | Final prescription schedule | Internet schedules do not control the label |
What belongs in this category
This is the label-arithmetic page. Five and ten milligrams describe total active in the vial; they do not reveal concentration, injection volume, amount per dose, frequency, or days of supply.
Compare the full number chain on the patient label. A larger vial is useful only when its concentration and prescribed cadence produce more usable days before the beyond-use date.
What these molecules are
TB-500 commonly refers to an acetylated seven-amino-acid sequence related to residues 17–23 of thymosin beta-4. Full thymosin beta-4 is a 43-amino-acid protein. The non-acetylated LKKTETQ fragment used in some laboratory work is also not automatically identical to an acetylated finished vial.
That is why a TB-500 label needs more than a brand-like name. Exact sequence or substance, concentration, fill volume, total active, and prescription directions must agree.
What the research measured
TB-500's research interest comes from its relationship to thymosin beta-4's actin-binding region and the cell-migration, cytoskeletal, angiogenesis, and wound biology around that sequence. Direct fragment evidence is mixed: a fibroblast scratch assay at 50 micrograms per milliliter for eight hours found no significant wound-closure difference from vehicle, and FDA's review identified no human TB-500 study.
Frequently cited wound work tested full thymosin beta-4 or a non-acetylated fragment in laboratory or animal models. Human thymosin beta-4 wound studies therefore cannot be credited to TB-500 injection vials. Package size and weekly convenience change ownership facts, not this evidence boundary.
Which option wins this comparison
Choose a TB-500 vial only after exact identity is verified. Among verified options, the practical winner covers the prescribed course at the lower cost per day without exceeding the beyond-use date or creating avoidable refill gaps.
The 10 mg vial wins on supply only when the extra quantity is usable. The 5 mg vial wins when it better matches a shorter course or avoids waste. A weekly option wins only if the current label—not an internet protocol—prescribes weekly use.
Strength, concentration, and dose are different facts
Keep total active, concentration, injection volume, amount per dose, and frequency separate. Syringe units are volume markings and cannot be copied between concentrations. Ask the dispensing pharmacy to reconcile the label if the math is unclear.
Do not infer a schedule from thymosin beta-4 studies, a competitor's vial, or a forum stack. Do not double after a missed dose or combine TB-500 with another active in one syringe unless the prescription explicitly directs it.
What the routine changes in real life
The practical TB-500 routine includes injection days, clean preparation, site rotation, sharps disposal, storage, travel, and refill lead time. Count those handling events across the full course.
A lower-frequency schedule can materially reduce handling burden and make the routine easier to remember. If work or travel repeatedly breaks the prescribed cadence, ask the care team to adjust the plan instead of clustering doses.
Storage, shipping, and travel
Use the finished TB-500 vial's exact storage and after-opening instructions. Do not borrow a temperature range from BPC-157, KPV, or full thymosin beta-4. Keep the lot and beyond-use date with the original label.
After excess heat, freezing, a broken seal, crack, leak, cloudiness, particles, or color change, hold the dose and contact the dispensing pharmacy. During travel, prevent direct vial-to-ice contact and plan for clean syringe and sharps handling.
Side effects and urgent symptoms
No identified human TB-500 study establishes systemic safety. Immediate injection risks include pain, bruising, bleeding, irritation, contamination, and infection. Spreading warmth or redness, drainage, red streaking, fever, facial swelling, breathing difficulty, or fainting needs prompt help.
Tested athletes must also account for anti-doping rules. Pregnancy, breastfeeding, cancer or immune treatment, clotting concerns, and medication interactions require direct prescriber review.
Price, supply, and refills
Calculate price per prescribed day from verified supply, not the vial's milligram headline. Include syringes, swabs, shipping, storage equipment if needed, and the number of refills required for the course.
A larger vial is better value only when the concentration, schedule, and beyond-use date allow the full amount to be used. Otherwise the lower per-milligram price can hide waste.
Questions people ask before starting
Can I take BPC-157 and TB-500 every day?
Use TB-500 or BPC-157 only on the exact schedule printed on the prescription label. The compounds have different identities and historical schedules, and an online daily stack does not establish a safe or effective course. Do not turn the comparison into an unstudied home-mixed stack. The current vial label—not a historical protocol—sets the actual cadence.
What are the risks of taking TB-500?
No human TB-500 exposure, pharmacokinetic, safety, or efficacy study was identified in FDA's review. That leaves systemic risks undefined in addition to ordinary injection risks such as pain, bruising, contamination, and infection. TB-500 is also prohibited for tested athletes. Package size and weekly convenience do not resolve the missing human systemic data.
Is TB-500 the same as thymosin beta-4?
No. TB-500 commonly refers to a seven-amino-acid fragment related to residues 17–23 of thymosin beta-4. Thymosin beta-4 is a 43-amino-acid protein, so its human wound studies cannot be presented as TB-500 trials. Exact identity must be verified before comparing concentration, supply, or price.
What changes between 5 mg and 10 mg vials?
Five and ten milligrams usually describe total active in the vial, not the amount used at one time. Compare concentration, prescribed dose, frequency, days of supply, price per day, and refill timing before deciding which package is more practical. That arithmetic decides which package is more practical. For a vial-size decision, the winning package is the one that covers the prescribed course without waste.
Is a 10 mg TB-500 vial a higher dose than a 5 mg vial?
Not by itself. Ten milligrams states the total quantity in the vial. The prescribed dose depends on concentration, injection volume, active amount per use, and frequency. A larger vial may provide more doses at the same amount, or it may use a different fill volume. Never change syringe volume because the vial contains more total active.
Is TB-500 supposed to be injected weekly?
Only if the final prescription says so. Historical protocols and seller charts do not determine the current finished product's schedule. A weekly cadence can reduce handling burden, but it does not prove stronger results or apply across concentrations. Confirm what happens after a missed dose before travel or the first injection day.
How can a label prove the vial is actually TB-500?
The label and product documentation should identify the exact substance, not merely say “thymosin.” TB-500 commonly refers to an acetylated seven-amino-acid fragment related to thymosin beta-4, while the parent protein contains 43 amino acids. Concentration, fill volume, total active, and prescription directions should all be internally consistent.
What should happen to TB-500 during travel?
Carry it in the original labeled container, follow the exact temperature range, prevent direct contact with ice, and keep clean syringes separate from used sharps. Check airline and destination requirements. After excess heat, accidental freezing, a leak, crack, broken seal, cloudiness, particles, or color change, hold the dose for pharmacy guidance.
Separate vial size from concentration and schedule
A five-milligram vial and ten-milligram vial answer only one question: total labeled active. To compare them, write the concentration, fill volume, prescribed milliliter amount, injections per week, and pharmacy-stated days of supply in adjacent columns. A ten-milligram vial at a lower concentration can require a larger syringe volume than a five-milligram vial. A larger container can also leave unusable remainder if the beyond-use date arrives first. Confirm that the exact substance is TB-500 rather than full thymosin beta-4 or an unspecified "thymosin" product; milligram arithmetic cannot repair an identity mismatch. Price should be calculated per usable prescribed week, including supplies and shipping, not per headline milligram. If any number is missing, the comparison is incomplete.
A label identity checklist for TB-500
Look for the full active name, not just "thymosin peptide." Record sequence or recognized substance description, acetylation if stated, concentration, total fill, lot, preparation date, beyond-use date, and storage range. Then compare those facts with the prescription. If supporting literature studied full thymosin beta-4 or an unacetylated LKKTETQ fragment, mark it as a different evidence record. This identity check comes before five-versus-ten-milligram arithmetic. A precisely measured quantity of the wrong or unspecified molecular form does not become a valid comparison.
Use a quantity worksheet, not mental math
Write total milligrams, milligrams per milliliter, milliliters per injection, injections per interval, and usable calendar days on separate lines. Carry units through each multiplication so an accidental milligram-to-microgram or milliliter-to-syringe-mark error is visible. Then compare the calculated total with the package quantity and stated supply. This worksheet answers whether five or ten milligrams fits the prescription. It cannot answer whether TB-500 works, whether the schedule is supported, or whether the label names the correct molecular form.
Bottom line
TB-500 brings a distinctive actin-fragment rationale to recovery. The best vial makes that identity concrete with a coherent concentration, injection volume, prescribed amount, usable supply, storage plan, and refill rhythm.
Keep reading
- BPC-157 Injection Labels: Strength, Concentration, and Supply
- BPC-157 Injection Supplies and Storage
- How to Compare Peptide Vial Sizes Without Guessing the Dose
Primary sources
- https://pubmed.ncbi.nlm.nih.gov/12581423/
- https://pubmed.ncbi.nlm.nih.gov/14500546/
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list